NeuroSense Therapeutics Ltd. Regains Nasdaq Compliance: Key Financial Insights

Here are the key insights extracted from the financial report of NeuroSense Therapeutics Ltd.:

1. Filing Type: The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC, specifically under the Securities Exchange Act of 1934.
2. Date of Report: The report is dated January 6, 2025.
3. Company Information:

• Name: NeuroSense Therapeutics Ltd.
• Address: 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
• Contact: Phone number provided is +972-9-7996183.

4. Compliance Update: The key announcement made by NeuroSense Therapeutics Ltd. is that the company has regained compliance with Nasdaq’s minimum equity requirement and is now in compliance with all other Nasdaq listing requirements. This is a significant development as it indicates the company is meeting the necessary standards to remain listed on the exchange.
5. Incorporation by Reference: The report includes a statement that it will be incorporated by reference into the company's Registration Statements on Form S-8 and Form F-3, which are details concerning securities offerings.
6. Signature: The report is signed by Alon Ben-Noon, the Chief Executive Officer of NeuroSense Therapeutics Ltd., confirming the authenticity and approval of the report.

This information highlights the company's regulatory compliance status and its ongoing efforts to maintain its listing on the Nasdaq, which is crucial for investor confidence and market perception.